CD36 single nucleotide polymorphism is associated with variation in low-density lipoprotein-cholesterol in young Japanese men

Macrophages uptake oxidized low-density lipoprotein (LDL) via a scavenger receptor such as CD36 from plasma, and then become foam cells. We examined the association of CD36 gene single nucleotide polymorphisms (SNPs) with certain metabolic characteristics in a young male Japanese population (n = 494). The G allele in a SNP located at +30215 on the 3’-untranslated region (UTR) was significantly correlated with the plasma LDL-cholesterol concentrations (r = 0.13, p <0.01). The difference in LDL-cholesterol concentrations was 10 mg dl−1 between GG- and AA-genotype carriers (p <0.05). The CD36 gene SNP is a novel maker of the variation in the LDL-cholesterol levels in young Japanese men.

[1]  J. Dyck,et al.  Increased Hepatic CD36 Expression Contributes to Dyslipidemia Associated With Diet-Induced Obesity , 2007, Diabetes.

[2]  S. Hazen,et al.  Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype , 2007, Nature Medicine.

[3]  K. Safranow,et al.  Molecular Basis of Human CD36 Gene Mutations , 2007, Molecular medicine.

[4]  T. Saruta,et al.  Cellular insulin resistance in Epstein-Barr virus-transformed lymphoblasts from young insulin-resistant Japanese men. , 2005, Metabolism: clinical and experimental.

[5]  C. Dina,et al.  Genetic study of the CD36 gene in a French diabetic population. , 2004, Diabetes & metabolism.

[6]  F. D. de Beer,et al.  Low-Density Lipoprotein From Apolipoprotein E–Deficient Mice Induces Macrophage Lipid Accumulation in a CD36 and Scavenger Receptor Class A–Dependent Manner , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[7]  P. Froguel,et al.  A CD36 nonsense mutation associated with insulin resistance and familial type 2 diabetes , 2004, Human mutation.

[8]  P. Froguel,et al.  A promoter polymorphism in CD36 is associated with an atherogenic lipid profile in a French general population. , 2004, Atherosclerosis.

[9]  K. Adeli,et al.  Emergence of the metabolic syndrome in childhood: an epidemiological overview and mechanistic link to dyslipidemia. , 2003, Clinical biochemistry.

[10]  U. Wiklund,et al.  Does the autonomic nervous system play a role in the development of insulin resistance? A study on heart rate variability in first‐degree relatives of Type 2 diabetes patients and control subjects , 2003, Diabetic medicine : a journal of the British Diabetic Association.

[11]  T. Nakata,et al.  Insulin sensitivity and lipid metabolism in human CD36 deficiency. , 2003, Diabetes care.

[12]  G. Lewis,et al.  Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. , 2002, Endocrine reviews.

[13]  J. Strong,et al.  Natural history and risk factors of atherosclerosis in children and youth: the PDAY study. , 2002, Pediatric pathology & molecular medicine.

[14]  M. Esler,et al.  Sympathetic nervous system and insulin resistance: from obesity to diabetes. , 2001, American journal of hypertension.

[15]  C. Gissi,et al.  Structural and functional features of eukaryotic mRNA untranslated regions. , 2001, Gene.

[16]  N. Webb,et al.  CD36 does not play a direct role in HDL or LDL metabolism. , 2001, Journal of lipid research.

[17]  T. Aitman.  CD36, insulin resistance, and coronary heart disease , 2001, The Lancet.

[18]  T. Kurtz,et al.  Transgenic rescue of defective Cd36 ameliorates insulin resistance in spontaneously hypertensive rats , 2001, Nature Genetics.

[19]  H. Chiba,et al.  Human CD36 deficiency is associated with elevation in low-density lipoprotein-cholesterol. , 2000, American journal of medical genetics.

[20]  S. Hazen,et al.  Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. , 2000, The Journal of clinical investigation.

[21]  A. Bonen,et al.  Muscle-specific Overexpression of FAT/CD36 Enhances Fatty Acid Oxidation by Contracting Muscle, Reduces Plasma Triglycerides and Fatty Acids, and Increases Plasma Glucose and Insulin* , 1999, The Journal of Biological Chemistry.

[22]  M. Miyagawa,et al.  Relationship between insulin resistance and cardiac sympathetic nervous function in essential hypertension. , 1999, Journal of hypertension.

[23]  D. Gómez-Coronado,et al.  Human CD36 is a high affinity receptor for the native lipoproteins HDL, LDL, and VLDL. , 1998, Journal of lipid research.

[24]  D. Gómez-Coronado,et al.  CLA-1 is an 85-kD plasma membrane glycoprotein that acts as a high-affinity receptor for both native (HDL, LDL, and VLDL) and modified (OxLDL and AcLDL) lipoproteins. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[25]  M. Vranic,et al.  Fatty Acids Mediate the Acute Extrahepatic Effects of Insulin on Hepatic Glucose Production in Humans , 1997, Diabetes.

[26]  J. Strong,et al.  Atherosclerosis of the aorta and coronary arteries and cardiovascular risk factors in persons aged 6 to 30 years and studied at necropsy (The Bogalusa Heart Study). , 1992, The American journal of cardiology.

[27]  H. Ikeda,et al.  Membrane glycoprotein CD36: a review of its roles in adherence, signal transduction, and transfusion medicine. , 1992, Blood.

[28]  H. Ikeda,et al.  A New Platelet‐Specific Antigen, Naka, Involved in the Refractoriness of HLA‐Matched Platelet Transfusion , 1989, Vox sanguinis.

[29]  James Scott,et al.  Identification of Cd36 (Fat) as an insulin-resistance gene causing defective fatty acid and glucose metabolism in hypertensive rats , 1999, Nature Genetics.

[30]  G. Lewis,et al.  Interaction between free fatty acids and insulin in the acute control of very low density lipoprotein production in humans. , 1995, The Journal of clinical investigation.

[31]  Y. Tomiyama,et al.  A platelet membrane glycoprotein (GP) deficiency in healthy blood donors: Naka- platelets lack detectable GPIV (CD36). , 1990, Blood.